The Pharma Letter2d
Growing emphasis on disease-modifying therapies in Parkinson’s
The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective ...
BioSpace9d
7 Alzheimer’s and Parkinson’s Programs Discarded in 2024
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...
Messenger News4d
Parkinson education program Wednesday
The Iowa Chapter of the American Parkinson Disease Association is holding a Parkinson education program from 1 to 3:30 p.m. Wednesday at the Fort Dodge Public Library, 424 Central Ave. The event is ...
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024.
DelveInsight Business Research, LLP: Global Neurological Biomarkers Market to Surpass USD 16 Billion Mark by 2030 | DelveInsight
The neurological biomarkers market is expanding as neurological disorders, including dementia and Parkinson's disease, become more prevalent with an aging global population. Innovations in biomarker ...
The Korea Herald11d
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update
A comprehensive update of HanAll's public pipeline development below includes an overview of research along with lists ... is ...
The Korea Bizwire6d
AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9
(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB ...
IRLAB Therapeutics: IRLAB Publishes Interim Report for the Period January - September 2024
GOTHENBURG, SWEDEN / ACCESSWIRE / October 30, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments ...